IRadimed Corp. (IRMD)

IRadimed Corp. reported record revenue for Q4 2025 and Q1 2026, along with record GAAP diluted EPS. A special cash dividend was approved, and the regular quarterly cash dividend was increased. The commercial launch of the next-generation 3870 MRI-compatible IV infusion pump system occurred in Q1 2026. The company reaffirmed its full-year 2026 revenue and GAAP diluted EPS guidance. IRadimed participated in the 38th Annual Roth Conference and the 25th Annual Needham Virtual Healthcare Conference. The stock experienced a decline in the 30 and 90 days leading up to May 6, 2026, despite a strong 1-year total shareholder return.

Demand for IRadimed Corp.'s products is influenced by the capital spending budgets of its customers, government funding policies, and broader product and economic cycles. The available quarterly revenue data does not indicate a strong traditional seasonal pattern, with the company showing consistent revenue growth across reported quarters.

IRadimed Corp. operates in the Healthcare sector, specifically in the Medical Devices and Instruments industry, developing, manufacturing, marketing, and distributing MRI-compatible medical devices. Its major products include MRidium MRI compatible intravenous (IV) infusion pump systems, MRI compatible patient vital signs monitoring systems, and the 3600 FMD1 ferromagnetic detection device. Related accessories such as non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories are also offered. IRadimed is the only known provider of non-magnetic IV infusion pump systems and patient vital signs monitors specifically designed for use during MRI procedures.

IRadimed Corp. sells its products to hospitals and acute care facilities in the United States and internationally, with the majority of its revenue generated from the United States. Its international distribution network spans across the Americas, Europe, Middle East, Africa, and Asia, and Oceania.

IRadimed Corp. has received positive recognition for its growth and innovation, including being named on Forbes' list of America's Most Successful Small-Cap Companies for 2024 and TIME's list of America's Growth Leaders for 2026. No specific events negatively impacting IRadimed Corp.'s brand reputation in the past year were found in the search results.

IRadimed Corp. has significant institutional ownership, with 213 institutional owners and shareholders holding a total of 7,165,527 shares as of April 30, 2026. Major institutional owners include BlackRock, Inc. and Vanguard Group Inc. Individual insiders, including CEO Roger Susi, hold a substantial portion of the company's shares. There have been insider sales reported in the past six months.